Trial of AD036 in Obstructive Sleep Apnea

This was a randomized, double-blind, placebo-controlled, repeat-dose, parallel arm, outpatient and inpatient, multicenter, dose-finding study of the combination of atomoxetine and oxybutynin in adults with OSA documented by polysomnography (PSG). Approximately 140 subjects were to be randomized 1:1:1:1 to receive 1 of 3 different fixed-dose combinations of oxybutynin and atomoxetine or matching placebo. For all subjects, the study consisted of: * A screening and baseline period in which subjects' eligibility was determined * An initial 2-night, at-home blinded baseline period in which all subjects received placebo * A 3-night, run-in period in which subjects received: * Low-dose combination for subjects randomized to one of the 3 study treatment arms * Placebo for subjects randomized to the placebo treatment arm * A 7-night treatment period in which subjects received the treatment to which they were randomized, i.e., 1 of the 3 different fixed-dose combinations of drugs, or placebo * An end of study visit